Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
entities : Bristol-myers squibb company crawled time : 15:20 save search
Strategic Analysis of Global Oral Anticoagulants Market Size Projected to Reach USD 34.1 Billion by 2028, Predicts Facts & Factors
Published: 2023-04-05 (Crawled : 15:20) - prnewswire.com
SNYNF | News | $94.25 -2.18% 480
|
Health Technology
|
| O: 0.69%
H: 0.0%
C: 0.0%
JNJ | News | $148.53 -0.69% -0.14% 9.6M
|
Health Technology
|
| O: 3.71%
H: 0.78%
C: 0.75%
BMY | $48.86 -0.27% -0.02% 16M
|
Health Technology
|
| O: 0.8%
H: 1.07%
C: 0.52%
ABT | News | $106.89 -0.65% -0.22% 5.1M
|
Health Technology
|
| O: -0.17%
H: 1.62%
C: 1.54%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: 1.58%
H: 0.0%
C: 0.0%
global market
Melanoma to be the Most Promising Indication for the PD-1/PDL-1 Inhibitor Therapies in the U.S. and EU-5 Region - Exclusive DeepTech M-A-PTM Analysis by BIS Research
Published: 2022-10-07 (Crawled : 15:20) - prnewswire.com
GLAXF | News | $19.54 -14.18% 2.6K
|
Health Technology
|
| O: 6.33%
H: 0.0%
C: 0.0%
GSK | News | $40.86 -0.92% -0.15% 1.7M
|
Health Technology
|
| O: 0.63%
H: 0.76%
C: -0.26%
BMY | $48.86 -0.27% -0.02% 16M
|
Health Technology
|
| O: 0.14%
H: 0.16%
C: -0.91%
RCUS 4 | $15.43 -0.45% 0.0% 520K
|
Health Technology
|
| O: -1.93%
H: 0.53%
C: -5.94%
INCY | $51.72 0.14% 0.14% 1.5M
|
Health Technology
|
| O: -0.72%
H: 0.38%
C: -1.04%
AGEN A | $7.42 14.86% 12.94% 1.3M
|
Health Technology
|
| O: -1.78%
H: 1.45%
C: -2.55%
melanoma research
Antiviral Drugs Market is expected to grow at a steady pace by 2027 | CAGR: 3.4% | UnivDatos Market Insights
Published: 2022-05-30 (Crawled : 15:20) - prnewswire.com
GLAXF | News | $19.54 -14.18% 2.6K
|
Health Technology
| Email alert
Add to watchlist
JNJ | News | $148.53 -0.69% -0.14% 9.6M
|
Health Technology
| Email alert
Add to watchlist
BMY | $48.86 -0.27% -0.02% 16M
|
Health Technology
| Email alert
Add to watchlist
ABBV | News | $167.8 -1.03% -0.06% 4.1M
|
Health Technology
| Email alert
Add to watchlist
GSK | News | $40.86 -0.92% -0.15% 1.7M
|
Health Technology
| Email alert
Add to watchlist
antiviral expected market drug
Neoadjuvant Opdivo (nivolumab) with Chemotherapy Significantly Improves Event-Free Survival in Patients with Resectable Non-Small Cell Lung Cancer in Phase 3 CheckMate -816 Trial
Published: 2022-04-11 (Crawled : 15:20) - biospace.com/
BMY | $48.86 -0.27% -0.02% 16M
|
Health Technology
|
| O: -0.09%
H: 0.55%
C: -1.54%
opdivo trial cancer phase 3 nivolumab
Gainers vs Losers
| 63% | 37% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.